A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy
This is a pharmacogenomic phase II, multicenter, prospective clinical trial whose main
objective is to evaluate the association of molecular and imaging markers with the response
to bevacizumab administration in combination with docetaxel and doxorubicin as neoadjuvant
chemotherapy in patients diagnose with locally advanced breast cancer.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Evaluation of SNPs genotyping.
The analysis of genetic differences will be determined through analysis of single nucleotide polymorphisms. It will be assesed before starting the treatment using Affymetrix's Human Mapping 500k array set.
This evaluation will be performed within 14 days before start of treatment
No
Antonio Anton, MD
Principal Investigator
Hospital Miguel Servet
Spain: Spanish Agency of Medicines
ML22197/2009-01
NCT01338753
October 2009
August 2012
Name | Location |
---|